Kephera Diagnostics

Kephera Diagnostics is a commercial-stage, private diagnostics company targeting significant unmet needs in infectious diseases and women's health. Its core strategy involves developing novel immunoassays, including point-of-care and ELISA formats, and offering them through its own certified clinical laboratory. The company has launched several first-to-market tests, including a blood-based diagnostic for endometriosis (EndomTest™) and comprehensive panels for parasitic infections like Chagas disease and liver fluke, supported in part by NIH grants. Kephera's model combines proprietary test development with a revenue-generating laboratory services business.

Immunoassay development for serological diagnosis, focusing on ELISA and point-of-care formats for complex infectious diseases and women's health conditions. Expertise includes multi-analyte panels and confirmatory "tiebreaker" tests.

In parasitic disease diagnostics, Kephera faces limited direct competition due to the neglected nature of these diseases, competing mainly against older, less accurate tests and a few specialized labs. In women's health and Lyme disease, the competitive landscape is more intense, with larger, established diagnostic companies (e.g., Quest, LabCorp, Abbott, Roche) and several biotechs developing non-invasive endometriosis tests and improved Lyme assays.